Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; human immunoglobulin a - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a-routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals, household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, admin

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 320 mg - injection, solution - excipient ingredients: glycine; human immunoglobulin a - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a-routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals, household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, admin

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - fomepizole, quantity: 1 g/ml - injection - excipient ingredients: - antizol is indicated for the treatment of ethylene glycol or methanol poisoning. (see dosage and administration).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mavlab pty. ltd. - oxytetracycline - oral powder, pre-mix - oxytetracycline antibiotic active 93.0 g/kg - antibiotic & related - calf | pigs | poultry broilers (meat for human consum) | poultry layers (eggs for human consump) | beef calf | boar | bovine | c - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds

United States - English - NLM (National Library of Medicine)

king bio inc. - artemisia abrotanum flowering top (unii: qg07g580u0) (artemisia abrotanum flowering top - unii:qg07g580u0), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), corticotropin (unii: k0u68q2txa) (corticotropin - unii:k0u68q2txa), .alpha.-ketoglutaric acid (unii: 8id597z82x) (.alpha.-ketoglutaric acid - unii:8id597z82x), .alpha.-lipoic acid (unii: 73y7p0k73y) (.alpha.-lipoic acid - unii:73y7p0k73y), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), calcium fluoride (unii: - artemisia abrotanum flowering top 10 [hp_x] in 59 ml - uses a natural aid for premature aging: wrinkles, brown spots, dry skin, dull, grey or thinning hair. uses   a natural aid for premature aging: - wrinkles - brown spots - dry skin - dull, grey or thinning hair

United States - English - NLM (National Library of Medicine)

king bio inc. - artemisia abrotanum flowering top (unii: qg07g580u0) (artemisia abrotanum flowering top - unii:qg07g580u0), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), corticotropin (unii: k0u68q2txa) (corticotropin - unii:k0u68q2txa), .alpha.-ketoglutaric acid (unii: 8id597z82x) (.alpha.-ketoglutaric acid - unii:8id597z82x), .alpha.-lipoic acid (unii: 73y7p0k73y) (.alpha.-lipoic acid - unii:73y7p0k73y), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), calcium fluoride (unii: - artemisia abrotanum flowering top 10 [hp_x] in 59 ml - uses a natural aid for premature aging: - wrinkles - brown spots - dry skin - dull, grey or thinning hair - low vitality - poor memory - dullness - sleeplessness - weak bones - low libido - lack of appetite - fatigue - joint and muscle pain drug facts __________________________________________________________________________________________________________________ hpus active ingredients                                                                   purpose equal volumes of each hpus** ingredient in 10x, 30x, and 1lm potencies unless otherwise noted. abrotanum.....................wrinkles, flabby skin, hair loss, stiffness adrenalinum ................slow pulse, anemia, high blood pressure adrenocorticotrophin (30x) .......pale, thin skin, sexual disorders alpha-ketoglutaricum acidum............ constipation, forgetfulness alpha-lipoicum acidum ..................mentally jittery, restless sleep baryta carboni

United States - English - NLM (National Library of Medicine)

u.s. pharmaceuticals - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix pregnancy category c. there are no adequate and well-controlled studies of chantix use in pregnant women. in animal studies, chantix caused decreased fetal weights, increased auditory startle response, and decreased fertility in offspring. chantix should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in reproductive and developmental toxicity studies, pregnant rats and rabbits received varenicline succinate during organogenesis at oral doses up to 15 and 30 mg/kg/day, respectively. these exposures were 36 (rats) and 50 (rabbits) times the human exposure (based on auc) at the maximum recommended human dose (mrhd) of 1 mg twice daily. while no fetal structural abnormalities occurred in either species, reduced fetal weights occurred in rabbits at the highest dose (e

United States - English - NLM (National Library of Medicine)

rebel distributors corp - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix pregnancy category c. there are no adequate and well-controlled studies of chantix use in pregnant women. in animal studies, chantix caused decreased fetal weights, increased auditory startle response, and decreased fertility in offspring. chantix should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in reproductive and developmental toxicity studies, pregnant rats and rabbits received varenicline succinate during organogenesis at oral doses up to 15 and 30 mg/kg/day, respectively. these exposures were 36 (rats) and 50 (rabbits) times the human exposure (based on auc) at the maximum recommended human dose (mrhd) of 1 mg bid. while no fetal structural abnormalities occurred in either species, reduced fetal weights occurred in rabbits at the highest dose (exposures 5

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix pregnancy category c. there are no adequate and well-controlled studies of chantix use in pregnant women. in animal studies, chantix caused decreased fetal weights, increased auditory startle response, and decreased fertility in offspring. chantix should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in reproductive and developmental toxicity studies, pregnant rats and rabbits received varenicline succinate during organogenesis at oral doses up to 15 and 30 mg/kg/day, respectively. these exposures were 36 (rats) and 50 (rabbits) times the human exposure (based on auc) at the maximum recommended human dose (mrhd) of 1 mg bid. while no fetal structural abnormalities occurred in either species, reduced fetal weights occurred in rabbits at the highest dose (exposures

United States - English - NLM (National Library of Medicine)

rebel distributors corp - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix pregnancy category c. there are no adequate and well-controlled studies of chantix use in pregnant women. in animal studies, chantix caused decreased fetal weights, increased auditory startle response, and decreased fertility in offspring. chantix should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in reproductive and developmental toxicity studies, pregnant rats and rabbits received varenicline succinate during organogenesis at oral doses up to 15 and 30 mg/kg/day, respectively. these exposures were 36 (rats) and 50 (rabbits) times the human exposure (based on auc) at the maximum recommended human dose (mrhd) of 1 mg bid. while no fetal structural abnormalities occurred in either species, reduced fetal weights occurred in rabbits at the highest dose (exposures 5